189 related articles for article (PubMed ID: 31574418)
21. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
[TBL] [Abstract][Full Text] [Related]
22. Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Nilsson MP; Johnsson A; Scherman J
Radiat Oncol; 2021 Aug; 16(1):152. PubMed ID: 34399812
[TBL] [Abstract][Full Text] [Related]
23. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
24. Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.
Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):700-7. PubMed ID: 26382849
[TBL] [Abstract][Full Text] [Related]
25. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?
Dewas CV; Maingon P; Dalban C; Petitfils A; Peignaux K; Truc G; Martin E; Khoury C; Dewas S; Créhange G
Radiat Oncol; 2012 Nov; 7():201. PubMed ID: 23190693
[TBL] [Abstract][Full Text] [Related]
26. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Deenen MJ; Dewit L; Boot H; Beijnen JH; Schellens JH; Cats A
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):e201-7. PubMed ID: 23517808
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
[TBL] [Abstract][Full Text] [Related]
29. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
Graf R; Wust P; Hildebrandt B; Gögler H; Ullrich R; Herrmann R; Riess H; Felix R
Oncology; 2003; 65(1):14-22. PubMed ID: 12837978
[TBL] [Abstract][Full Text] [Related]
30. A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy.
Joseph K; Al Habsi Z; Abraham A; Elangovan A; Ghosh S; Pham T; Shreekumar D; Ramji Z; Paulson K; Tankel K; Usmani N; Severin D; Schiller D; Wong C; Mulder K; Karachiwala H; Doll C; King K; Nijjar T
Radiother Oncol; 2024 Jul; 196():110219. PubMed ID: 38479443
[TBL] [Abstract][Full Text] [Related]
31. Tolerability of ADXS11-001 Lm-LLO Listeria-Based Immunotherapy With Mitomycin, Fluorouracil, and Radiation for Anal Cancer.
Safran H; Leonard KL; Perez K; Vrees M; Klipfel A; Schechter S; Oldenburg N; Roth L; Shah N; Rosati K; Rajdev L; Mantripragada K; Sheng IY; Barth P; DiPetrillo TA
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1175-1178. PubMed ID: 29722659
[TBL] [Abstract][Full Text] [Related]
32. Treatment of the Primary Tumor in Anal Canal Cancers.
Glynne-Jones R; Rao S
Surg Oncol Clin N Am; 2017 Jan; 26(1):73-90. PubMed ID: 27889038
[TBL] [Abstract][Full Text] [Related]
33. The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy.
Weber DC; Kurtz JM; Allal AS
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):675-80. PubMed ID: 11395235
[TBL] [Abstract][Full Text] [Related]
34. Hematologic Nadirs During Chemoradiation for Anal Cancer: Temporal Characterization and Dosimetric Predictors.
Lee AY; Golden DW; Bazan JG; Kopec M; Pelizzari CA; Aggarwal S; Chang DT; Liauw SL
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):306-312. PubMed ID: 28068238
[TBL] [Abstract][Full Text] [Related]
35. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
El-Hadaad HA; Wahba HA; Roshdy S
J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
[TBL] [Abstract][Full Text] [Related]
36. Prospective phase II study of tomotherapy based chemoradiation treatment for locally advanced anal cancer.
Joseph K; Nijjar Y; Warkentin H; Schiller D; Tankel K; Usmani N; Severin D; Ghosh S; Syme A; Nijjar T; Mulder K; Doll C; Wong C; Field C
Radiother Oncol; 2015 Nov; 117(2):234-9. PubMed ID: 26306677
[TBL] [Abstract][Full Text] [Related]
37. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
Flam M; John M; Pajak TF; Petrelli N; Myerson R; Doggett S; Quivey J; Rotman M; Kerman H; Coia L; Murray K
J Clin Oncol; 1996 Sep; 14(9):2527-39. PubMed ID: 8823332
[TBL] [Abstract][Full Text] [Related]
38. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
39. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
Glynne-Jones R; Kadalayil L; Meadows HM; Cunningham D; Samuel L; Geh JI; Lowdell C; James R; Beare S; Begum R; Ledermann JA; Sebag-Montefiore D;
Ann Oncol; 2014 Aug; 25(8):1616-22. PubMed ID: 24827136
[TBL] [Abstract][Full Text] [Related]
40. [Epidermoid carcinomas of the anal canal treated with definitive radiation therapy in a series of 305 patients].
Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Houry S; Gallot D; Parc R; Huang R; Qu SH; Pène F; Schlienger M
Cancer Radiother; 2003 Aug; 7(4):237-53. PubMed ID: 12914857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]